The Role of Motility Impairment in the Pathogenesis of Functional Disorders of the Gastrointestinal Tract and Modern Possibilities for Their Treatment (Resolution of an Expert Council and Literature Review)
I. V. Maev,
A. S. Trukhmanov,
A. A. Sheptulin,
V. I. Simanenkov,
S. R. Abdulhakov,
N. A. Agafonova,
V. A. Akhmedov,
T. A. Ilchishina,
M. G. Ipatova,
O. V. Krapivnaya,
Yu. A. Kucheryavyi,
M. F. Osipenko,
O. A. Storonova,
G. N. Tarasova,
G. Ya. Khismatullina,
S. V. Cheryomushkin https://doi.org/10.22416/1382-4376-2019-29-6-7-14
Abstract
Aim. To present the materials of an Expert Council, which was held on September 23, 2019 in Istanbul (Turkey) under the auspices of a World Gastroenterology Organisation congress and the support of the Abbott company.
General provisions. During the work of the Expert Council, the role of motility disorders of the stomach and duodenum, intestines, gall bladder and the sphincter of Oddi in the development of functional diseases of the digestive system, such as functional dyspepsia (FD), irritable bowel syndrome (IBS), biliary dyskinesia (BD) was discussed, and the effectiveness of antispasmodics and prokinetics in their treatment was shown. At the same time, the advantages of the mebeverin antispasmodic drug, as well as the high efficiency and safety of the itopride hydrochloride prokinetic drug were noted. It is emphasized that, at the stage of a diagnostic search in the absence of “alarm symptoms” in patients with suspected FD, IBS, and BD, these drugs can be prescribed empirically.
Conclusions. When selecting pharmacotherapy for patients with motor impairment, it is extremely important to consider the nature of these disorders. The use of modern medical preparations, which are characterized by a high level of safety and the targeted action towards a specific motility disorder, allows optimal therapy results to be achieved with minimal risks for the patient.
General provisions. During the work of the Expert Council, the role of motility disorders of the stomach and duodenum, intestines, gall bladder and the sphincter of Oddi in the development of functional diseases of the digestive system, such as functional dyspepsia (FD), irritable bowel syndrome (IBS), biliary dyskinesia (BD) was discussed, and the effectiveness of antispasmodics and prokinetics in their treatment was shown. At the same time, the advantages of the mebeverin antispasmodic drug, as well as the high efficiency and safety of the itopride hydrochloride prokinetic drug were noted. It is emphasized that, at the stage of a diagnostic search in the absence of “alarm symptoms” in patients with suspected FD, IBS, and BD, these drugs can be prescribed empirically.
Conclusions. When selecting pharmacotherapy for patients with motor impairment, it is extremely important to consider the nature of these disorders. The use of modern medical preparations, which are characterized by a high level of safety and the targeted action towards a specific motility disorder, allows optimal therapy results to be achieved with minimal risks for the patient.
About the Authors
I. V. Maev
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Dr. Sci. (Med.), RAS Academician, Professor, Head of the Department of Propaedeutics of Internal Diseases and Gastroenterology
127473, Moscow, Delegatskaya str., 20 build. 1
A. S. Trukhmanov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Professor, Department of Internal Diseases Propedeutics
119435, Moscow, Pogodinskaya str., 1, build. 1
A. A. Sheptulin
I.M. Sechenov First
Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Department of Internal Diseases Propedeutics
119435, Moscow, Pogodinskaya str., 1, build. 1
V. I. Simanenkov
North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Head of the Department of Internal Diseases and Clinical Pharmacology
191015, St. Petersburg, Kirochnaya str., 41
S. R. Abdulhakov
Kazan State Medical University
Russian Federation
Russian Federation
Cand. Sci. (Med.), Senior Researcher, Genetic and Cell Technologies OpenLab Scientific Research Laboratory
420015, Kazan, Karla Marksa str., 74
N. A. Agafonova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Cand. Sci. (Med.), Assoc. Prof., Gastroenterological Department
117997, Moscow, Ostrovityanova str., 1
V. A. Akhmedov
Omsk State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Departmental Head, Department of Medical Rehabilitation, Centre for Advanced Studies and Professional Training
644099, Omsk, Lenina str., 12
T. A. Ilchishina
Medical Holding “SM-clinic” (“Med Kom”)
Russian Federation
Russian Federation
Cand. Sci. (Med.), Multidisciplinary
195279, St. Petersburg, Udarnikov ave., 19/1
M. G. Ipatova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Cand. Sci. (Med.), Assoc. Prof., Hospital Pediatrics Department named after V.A. Tabolin
117997, Moscow, Ostrovityanova str., 1
O. V. Krapivnaya
Road Clinical Hospital of JSC Russian Railways, Khabarovsk-1 station
Russian Federation
Dr. Sci. (Med.), Departmental Head, Gastroenterology Department, Principal external gastroenterologist, Far-Eastern Direction of healthcare of JSC Russian Railways.
680022, Khabarovsk, Voronezhskaya str., 49
Russian Federation
Dr. Sci. (Med.), Departmental Head, Gastroenterology Department, Principal external gastroenterologist, Far-Eastern Direction of healthcare of JSC Russian Railways.
680022, Khabarovsk, Voronezhskaya str., 49
Yu. A. Kucheryavyi
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Cand. Sci. (Med.), Assoc. Prof., Department of Internal Diseases Propaedeutics and Gastroenterology
127473, Moscow, Delegatskaya str., 20 build. 1
Russian Federation
Cand. Sci. (Med.), Assoc. Prof., Department of Internal Diseases Propaedeutics and Gastroenterology
127473, Moscow, Delegatskaya str., 20 build. 1
M. F. Osipenko
Novosibirsk State Medical University
Russian Federation
Dr. Sci. (Med.), Departmental Head, Department of Internal Diseases Propaedeutics
630091, Novosibirsk, Krasny ave., 52
Russian Federation
Dr. Sci. (Med.), Departmental Head, Department of Internal Diseases Propaedeutics
630091, Novosibirsk, Krasny ave., 52
O. A. Storonova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Cand. Sci. (Med.), Doctor, Department of Functional Diagnostics, V.H. Vasilenko Clinic of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology
119991, Moscow, Pogodinskaya str., 1, build. 1
G. N. Tarasova
Rostov State Medical Univesrity
Russian Federation
Dr. Sci. (Med.), Prof., Department of Internal Diseases Propaedeutics
344022, Rostov-on-Don, Suvorova str., 119/80
Russian Federation
Dr. Sci. (Med.), Prof., Department of Internal Diseases Propaedeutics
344022, Rostov-on-Don, Suvorova str., 119/80
G. Ya. Khismatullina
Bashkir State Medical University
Russian Federation
Russian Federation
Cand. Sci. (Med.), Assoc. Prof., Department of Polyclinic Medicine, Institute of Postgraduate Education
450008, Ufa, Lenina str., 3
S. V. Cheryomushkin
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Cand. Sci. (Med.), Assoc. Prof., Department of Internal Diseases Propaedeutics and Gastroenterology
127473, Moscow, Delegatskaya str., 20 build. 1
References
1. Stanghellini V., Chan F.K.L., Hasler W.L. Malagelada J.R., Suzuki H., Tack J., Talley N.J. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–92. DOI: 10.1053/j.gastro.2016.02.011.
2. Ivashkin V.T., Sheptulin A.A., Kiprianis V.A. Functional dyspepsia. Moscow: “MEDpress-inform”; 2017 (In Rus.)
3. Ivashkin V.T., Mayev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M., Kiprianis V.A., Okhlobystina O.Z. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50–61 (In Rus.) DOI: 10.22416/1382-4376-2017-27-1-50-61
4. Kanath S. Comparative evaluation of the efficacy and tolerability of itopride and metoclopramide in patients with non-ulcer dyspepsia. JAMA-India. 2003;(2):95–8.
5. Holtmann G., Talley N.J., Liebgrets T. et al. A placebocontrolled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354:832–40.
6. Ivashkin V.T., Sheptulin A.A., Trukhmanov A.S. The effectiveness of ganaton (itopride hydrochloride) in the treatment of patients with functional dyspepsia. Farmateka. 2009; 13: 50–4. (In Rus.)
7. Huang H., Lv B. Itopride therapy fir functional dyspepsia: A meta-analysis. Word J Gastroenterol. 2012;18:7371–7.
8. Kang S., Park B., Shin C.M. Helicobacter pylori eradication therapy for functional dyspepsia: A meta-analysis by region and H. pylori prevalence. J Clin Med. 2019;288(9). PII: E1423
9. Du L.J. et al. Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis. World J Gastroenterol. 2016;22(12):3486–95.
10. Buzás G.M. Quality of life in patients with functional dyspepsia: Short- and long-term effect of Helicobacter pylori eradication with pantoprazole, amoxicillin, and clarithromycin or cisapride therapy: A prospective, parallel-group study. Curr Ther Res Clin Exp. 2006;67(5):305–20.
11. Carbone F., Vandenberghe A., Holvoet L. et al. The therapeutic outcome of itopride in functional dyspepsia postprandial distress syndrome: a double-blind randomized, multicentre, placebo-controlled study. Gastroenterology. 2018;154(6, Suppl 1):S-91. DOI: 10.1016/S0016-5085(18)30751-0
12. Mayev I.V., Kucheryavy Yu.A., Tsukanov V.V. et al. The results of the “Odyssey” prospective observational programme: the effectiveness of mebeverin in patients with postcholecystectomy spasms. Ter arch. 2018;90(8):40–7 (In Rus.)
13. Cotton P. B., Elta G.H., Carter C.R. Galbladder and sphincter of Oddi disorders. Rome IV Functional gastrointestinal disorders: disorders of gut-brain interaction Gastroenterology. 2016;150:1420–9.
14. Ivashkin V.T., Mayev I.V., Shulpekova Y.O., Baranskaya Y.K., Okhlobystin A.V., Trukhmanov A.S., Lapina T.L., Sheptulin A.A. Diagnostics and treatment of biliary dyskinesia: clinical guidelines of the Russian gastroenterological Association. Ross z gastroenterol gepatol koloproktol. 2018;28(3):63–80 (In Rus.) DOI: 10.22416/1382-4376-2018-28-3-63-80
15. Lacy D.J., Mearin F., Chang L. Bowel disorders. Rome IV Functional gastrointestinal disorders: disorders of gutbrain interaction Gastroenterology. 2016;150:1393–407.
16. Ivashkin V.T., Shelygin Y.A., Baranskaya Y.K., Belousova Y.A., Beniashvili A.G., Vasilyev S.V., Golovenko A.O., Golovenko O.V., Grigoryev Y.G., Kostenko N.V., Lapina T.L., Loranskaya I.D., Lyashenko O.S., Mayev I.V., Poluektova Y.A., Rumyantsev V.G., Timerbulatov V.M., Trukhmanov A.S., Fomenko O.Y., Khalif I.L., Chashkova E.Y., Sheptulin A.A., Shifrin O.S., Yanovoy V.V. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Ross z gastroenterol gepatol koloproktol. 2017;27(5):76–93 (In Rus.) DOI: 10.22416/1382-4376-2017-27-5-76-93
Review
For citations:
Maev I.V., Trukhmanov A.S., Sheptulin A.A., Simanenkov V.I., Abdulhakov S.R., Agafonova N.A., Akhmedov V.A., Ilchishina T.A., Ipatova M.G., Krapivnaya O.V., Kucheryavyi Yu.A., Osipenko M.F., Storonova O.A., Tarasova G.N., Khismatullina G.Ya., Cheryomushkin S.V. The Role of Motility Impairment in the Pathogenesis of Functional Disorders of the Gastrointestinal Tract and Modern Possibilities for Their Treatment (Resolution of an Expert Council and Literature Review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):7-14. (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-6-7-14
Views:
2089
Email this article 
